Hence, patients who failed to respond to initial PD-1 inhibitor could still achieve a high response rate with the addition of a JAK inhibitor in NSCLC patients with tumor PD-L1 ≥50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.